PE20081200A1 - Sal de potasio cristalina de analogos de lipoxina a4 - Google Patents
Sal de potasio cristalina de analogos de lipoxina a4Info
- Publication number
- PE20081200A1 PE20081200A1 PE2007001704A PE2007001704A PE20081200A1 PE 20081200 A1 PE20081200 A1 PE 20081200A1 PE 2007001704 A PE2007001704 A PE 2007001704A PE 2007001704 A PE2007001704 A PE 2007001704A PE 20081200 A1 PE20081200 A1 PE 20081200A1
- Authority
- PE
- Peru
- Prior art keywords
- potassium salt
- refers
- crystalline potassium
- salt
- lipoxin
- Prior art date
Links
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 title abstract 3
- 229930184725 Lipoxin Natural products 0.000 title abstract 2
- 150000002639 lipoxins Chemical class 0.000 title abstract 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 abstract 2
- QDKWLJJOYIFEBS-UHFFFAOYSA-N 1-fluoro-4-$l^{1}-oxidanylbenzene Chemical class [O]C1=CC=C(F)C=C1 QDKWLJJOYIFEBS-UHFFFAOYSA-N 0.000 abstract 1
- 206010012442 Dermatitis contact Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 206010039085 Rhinitis allergic Diseases 0.000 abstract 1
- 208000024780 Urticaria Diseases 0.000 abstract 1
- 238000002441 X-ray diffraction Methods 0.000 abstract 1
- 208000002029 allergic contact dermatitis Diseases 0.000 abstract 1
- 201000010105 allergic rhinitis Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 235000011056 potassium acetate Nutrition 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
- C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
- C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
- C07C59/70—Ethers of hydroxy-acetic acid, e.g. substitutes on the ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
- C07C59/48—Unsaturated compounds containing hydroxy or O-metal groups containing six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/41—Preparation of salts of carboxylic acids
- C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Otolaryngology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
Abstract
SE REFIERE A UNA SAL DE POTASIO CRISTALINA DE FORMULA (I) EN DONDE R1 ES -O-, -S(O)t- O UNA CADENA DE ALQUILENO LINEAL O RAMIFICADA, DONDE t ES 0, 1 O 2; R2 ES ARILO O ARALQUILO OPCIONALMENTE SUSTITUIDOS CON ALQUILO, ALCOXI, HALO, ENTRE OTROS. LA SAL DE POTASIO CRISTALINA ES 2-((2S,3R,4E,6E,10E,12S)-13-(4-FLUOROFENOXI)-2,3,12-TRIHIDROXITRIDECA-4,6,10-TRIEN-8-INILOXI)ACETATO DE POTASIO CUYA FORMA DE ANHIDRATO SE CARACTERIZA POR UN PATRON DE DIFRACCION DE POLVOS POR RAYOS X CON UN PICO CARACTERISTICO A d = 26,7Å Y d = 3,7Å. SE REFIERE TAMBIEN A UN PROCEDIMIENTO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA. DICHA SAL ES ANALOGA DE LIPOXINA A4 SIENDO UTIL EN EL TRATAMIENTO DE DERMATITIS ALERGICA DE CONTACTO, RINITIS ALERGICA, URTICARIA, PSORIASIS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87283006P | 2006-12-04 | 2006-12-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20081200A1 true PE20081200A1 (es) | 2008-11-06 |
Family
ID=39076610
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2012000006A PE20120395A1 (es) | 2006-12-04 | 2007-12-03 | Sal de potasio cristalina de analogos de lipoxina a4 |
| PE2007001704A PE20081200A1 (es) | 2006-12-04 | 2007-12-03 | Sal de potasio cristalina de analogos de lipoxina a4 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2012000006A PE20120395A1 (es) | 2006-12-04 | 2007-12-03 | Sal de potasio cristalina de analogos de lipoxina a4 |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US7906678B2 (es) |
| EP (2) | EP2089350B1 (es) |
| JP (1) | JP5410984B2 (es) |
| KR (3) | KR20160054030A (es) |
| CN (1) | CN101553456B (es) |
| AR (1) | AR064116A1 (es) |
| AU (1) | AU2007327765B2 (es) |
| BR (1) | BRPI0719679A2 (es) |
| CA (1) | CA2670791C (es) |
| CL (1) | CL2007003468A1 (es) |
| CO (1) | CO6190608A2 (es) |
| CR (1) | CR10837A (es) |
| DO (1) | DOP2009000130A (es) |
| EA (1) | EA018615B1 (es) |
| EC (1) | ECSP099380A (es) |
| IL (1) | IL198434A (es) |
| MA (1) | MA31079B1 (es) |
| MX (1) | MX2009005911A (es) |
| MY (1) | MY147951A (es) |
| NO (1) | NO20092528L (es) |
| NZ (1) | NZ577338A (es) |
| PE (2) | PE20120395A1 (es) |
| SV (1) | SV2009003286A (es) |
| TN (1) | TN2009000167A1 (es) |
| TW (1) | TWI415833B (es) |
| UY (1) | UY30755A1 (es) |
| WO (1) | WO2008068041A1 (es) |
| ZA (1) | ZA200904689B (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20120395A1 (es) * | 2006-12-04 | 2012-05-23 | Bayer Ip Gmbh | Sal de potasio cristalina de analogos de lipoxina a4 |
| US20090036530A1 (en) * | 2006-12-04 | 2009-02-05 | Bayer Schering Pharma Aktiengesellschaft | Crystalline acid of lipoxin A4 analogs and method of making |
| EP2135610A1 (en) | 2008-06-20 | 2009-12-23 | Laboratorios Almirall, S.A. | Combination comprising DHODH inhibitors and methotrexate |
| EP2470189A4 (en) * | 2009-08-27 | 2013-01-23 | Merck Sharp & Dohme | METHOD FOR PRODUCING PROTEASE INHIBITORS OF HEPATITIS C VIRUS |
| EP2958560B1 (en) * | 2013-02-21 | 2019-05-08 | Forsyth Dental Infirmary for Children | Methods for increasing oral ostenogenesis using lipoxin a4 (lxa4) and its analogs |
| US20180078519A1 (en) * | 2015-03-18 | 2018-03-22 | The Forsyth Institute | Methods for Stabilizing Atherosclerotic Plaques Using Lipoxins, Resolvins, and Analogs Thereof |
| EP3454907B1 (en) * | 2016-06-03 | 2020-07-22 | Thetis Pharmaceuticals LLC | Compositions and methods relating to salts of specialized pro-resolving mediators of inflammation |
| CA3052271A1 (en) | 2017-01-31 | 2018-08-09 | The Brigham And Women's Hospital, Inc. | Alx receptor ligands define a biochemical endotype for inflammation-based diseases |
| CN111875530A (zh) * | 2020-08-17 | 2020-11-03 | 浙江朗华制药有限公司 | 一种普拉西坦水合物晶体及其制备方法 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5650435A (en) * | 1991-04-01 | 1997-07-22 | Madara; James L. | Modulation of inflammation related to columnar epithelia |
| US6048897A (en) | 1993-06-15 | 2000-04-11 | Brigham And Women's Hospital | Lipoxin compounds and their use in treating cell proliferative disorders |
| US5441951A (en) * | 1994-06-15 | 1995-08-15 | Brigham & Women's Hospital | Lipoxin compounds |
| DK0703897T3 (da) | 1993-06-15 | 2008-12-01 | Brigham & Womens Hospital | Lipoxinforbindelser med forlænget halveringstid |
| AU7215294A (en) | 1993-06-29 | 1995-01-24 | Brigham And Women's Hospital | Modulation of inflammation related to columnar epithelia |
| US6008205A (en) | 1997-04-04 | 1999-12-28 | The Brigham & Women's Hospital, Inc. | Polyisoprenyl phosphate stable analogs for regulation of neutrophil responses |
| US6236978B1 (en) * | 1997-11-14 | 2001-05-22 | New York University | System and method for dynamic profiling of users in one-to-one applications |
| US6006466A (en) * | 1998-08-20 | 1999-12-28 | Washecka; John | Concealed linear payout holder for fishing leader |
| SE9900274D0 (sv) | 1999-01-28 | 1999-01-28 | Astra Ab | New compound |
| ES2344138T3 (es) | 1999-03-18 | 2010-08-19 | The Brigham And Women's Hospital, Inc. | Analogos de 16-fenoxi-lipoxina para utilizacion medica. |
| US6387953B1 (en) | 1999-03-18 | 2002-05-14 | Brigham And Women's Hopsital | Inhibition of TNF-(α)-initiated neutrophil response |
| ES2246230T3 (es) | 1999-03-18 | 2006-02-16 | The Brigham And Women's Hospital, Inc. | Compuestos de lipoxina y su utilizacion. |
| ATE258791T1 (de) | 1999-11-09 | 2004-02-15 | Alcon Inc | Lipoxin-a4 und deren analoge zur behandlung von trockenen augen |
| EP1268393A2 (en) | 2000-03-20 | 2003-01-02 | Trustees Of Boston University | Lipoxin analogs and methods for the treatment of periodontal disease |
| US6831186B2 (en) * | 2001-11-06 | 2004-12-14 | Schering Aktiengesellschft | Lipoxin A4 analogs |
| AU2002347539A1 (en) | 2001-12-13 | 2003-06-23 | Ranbaxy Laboratories Limited | Crystalline cefdinir potassium dihydrate |
| ATE531713T1 (de) | 2002-03-15 | 2011-11-15 | Reddys Lab Ltd Dr | Polymorphin von 5-ä4-ää3-methyl-4-oxo-3,4- dihydrochinazolin-2-ylümethoxyübenzylü thiazolidin-2,4-dion kalium salz |
| ATE487478T1 (de) | 2003-01-30 | 2010-11-15 | Lek Pharmaceuticals | Herstellung eines neuen pharmazeutisch geeigneten losartan-salzes und von seinen formen mittels neuer reinigungs- und isolationsverfahren |
| WO2006035291A1 (en) | 2004-09-27 | 2006-04-06 | Ranbaxy Laboratories Limited | Crystalline forms of cefdinir potassium |
| US7223718B2 (en) * | 2005-03-07 | 2007-05-29 | Falcon Lab Llc | Enhanced glyphosate herbicidal concentrates |
| KR20070088764A (ko) | 2005-10-31 | 2007-08-29 | 테바 파마슈티컬 인더스트리즈 리미티드 | 세프디니어 칼륨염의 결정형 |
| PE20120395A1 (es) * | 2006-12-04 | 2012-05-23 | Bayer Ip Gmbh | Sal de potasio cristalina de analogos de lipoxina a4 |
-
2007
- 2007-12-03 PE PE2012000006A patent/PE20120395A1/es not_active Application Discontinuation
- 2007-12-03 UY UY30755A patent/UY30755A1/es not_active Application Discontinuation
- 2007-12-03 US US11/999,000 patent/US7906678B2/en active Active
- 2007-12-03 CL CL200703468A patent/CL2007003468A1/es unknown
- 2007-12-03 PE PE2007001704A patent/PE20081200A1/es not_active Application Discontinuation
- 2007-12-04 KR KR1020167011173A patent/KR20160054030A/ko not_active Ceased
- 2007-12-04 EA EA200900732A patent/EA018615B1/ru not_active IP Right Cessation
- 2007-12-04 WO PCT/EP2007/010785 patent/WO2008068041A1/en not_active Ceased
- 2007-12-04 MX MX2009005911A patent/MX2009005911A/es active IP Right Grant
- 2007-12-04 AR ARP070105403A patent/AR064116A1/es unknown
- 2007-12-04 KR KR1020097011427A patent/KR20090101169A/ko not_active Ceased
- 2007-12-04 TW TW096146154A patent/TWI415833B/zh not_active IP Right Cessation
- 2007-12-04 AU AU2007327765A patent/AU2007327765B2/en not_active Ceased
- 2007-12-04 BR BRPI0719679-2A2A patent/BRPI0719679A2/pt not_active IP Right Cessation
- 2007-12-04 EP EP07847057.2A patent/EP2089350B1/en active Active
- 2007-12-04 EP EP18190069.7A patent/EP3489214A1/en not_active Withdrawn
- 2007-12-04 JP JP2009539669A patent/JP5410984B2/ja not_active Expired - Fee Related
- 2007-12-04 NZ NZ577338A patent/NZ577338A/en not_active IP Right Cessation
- 2007-12-04 CA CA2670791A patent/CA2670791C/en not_active Expired - Fee Related
- 2007-12-04 MY MYPI20092224A patent/MY147951A/en unknown
- 2007-12-04 KR KR1020147030409A patent/KR20140135847A/ko not_active Ceased
- 2007-12-04 CN CN2007800448571A patent/CN101553456B/zh not_active Expired - Fee Related
-
2009
- 2009-04-28 IL IL198434A patent/IL198434A/en not_active IP Right Cessation
- 2009-04-29 TN TNP2009000167A patent/TN2009000167A1/fr unknown
- 2009-06-03 EC EC2009009380A patent/ECSP099380A/es unknown
- 2009-06-04 SV SV2009003286A patent/SV2009003286A/es unknown
- 2009-06-04 CR CR10837A patent/CR10837A/es unknown
- 2009-06-04 DO DO2009000130A patent/DOP2009000130A/es unknown
- 2009-06-04 CO CO09057912A patent/CO6190608A2/es not_active Application Discontinuation
- 2009-06-29 MA MA32056A patent/MA31079B1/fr unknown
- 2009-07-03 NO NO20092528A patent/NO20092528L/no not_active Application Discontinuation
- 2009-07-03 ZA ZA2009/04689A patent/ZA200904689B/en unknown
-
2011
- 2011-02-07 US US13/022,139 patent/US8049035B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20081200A1 (es) | Sal de potasio cristalina de analogos de lipoxina a4 | |
| PE20071176A1 (es) | Derivados diamina como inhibidores de leucotrieno a4 hidrolasa | |
| MX2013004242A (es) | Sulfonamidas nematocidas. | |
| PE20142042A1 (es) | Forma termodinamicamente estable de una sal tosilato de sorafenib | |
| PE20081532A1 (es) | Compuestos novedosos | |
| AR100790A2 (es) | COMPUESTOS HETEROCÍCLICOS, ACTIVOS COMO INHIBIDORES DE b-LACTAMAS | |
| MX2012006562A (es) | Formas cristalinas de 3-(2,6-dicloro-3,5-dimetoxi-fenil)-1-{6-[4-( 4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas. | |
| PE20040898A1 (es) | Nuevos compuestos derivados de pirimidina | |
| PE20070136A1 (es) | COMPUESTOS DERIVADOS DE N-(PIRIDIN-2-IL)-SULFONAMIDA COMO INHIBIDORES DE LA ENZIMA 11-beta-HIDROXIESTEROIDE DESHIDROGENASA HUMANA TIPO 1 | |
| AR109135A2 (es) | Forma sólida de una sal hidratada de tartrato de un compuesto de pirrolidina inhibidor de dpp-iv | |
| MA32350B1 (fr) | Composition et methode de lutte contre les organismes nuisibles | |
| UA99930C2 (ru) | Фунгицидная композиция и способы борьбы с вредными грибами | |
| CY1109307T1 (el) | Χρηση αδαπαλενιου για τη θεραπεια δερματολογικων διαταραχων | |
| PE20081475A1 (es) | Arilamidas sustituidas por tiazol u oxazol | |
| EA200602038A1 (ru) | Азинилимидазоазины и азинилкарбоксамиды | |
| NZ599797A (en) | Isoxazoline compositions and their use as antiparasitics | |
| BR0306559A (pt) | Forma de aplicação oral para etilésteres de ácido 3-[(2-{[4-(hexiloxicarbonilamino-imino-metil)-fenilamin o]-metil}-1-metil-1h-ben-zimidazol-5-carbonil)-piridin- 2-il-amino]-propiÈnico e seus sais | |
| PE20080364A1 (es) | Acido bifenilcarboxilicos substituidos y sus derivados como moduladores de la actividad de la gamma-secretasa | |
| ATE520406T1 (de) | Kristalline form des ibandronat-natriums | |
| AR047085A1 (es) | Derivados de (3-oxo-3,4-dihidro-quinoxalina-2-il-amino)benzamida y compuestos relacionados como inhibidores de glucogeno fosforilasa para el tratamiento de diabetes y obesidad | |
| ATE403375T1 (de) | Pestizide zusammensetzung enthaltend einen laktat ester als kristallwachstumshemmer | |
| ECSP11011383A (es) | Sal de sodio de ácido 5-ciclopropil-2-{[2-(2,6-difluorofenil)pirimidin-5-il]amino}benzoico como inhibidor de dhodh | |
| IN2014CN03646A (es) | ||
| EP2075328A4 (en) | NEW MICROORGANISM WITH ABILITY TO REMOVE DIPHENYLARSIC ACID | |
| PE20080175A1 (es) | Sales de malato, y polimorfos de acido (3s,5s)-7-[3-amino-5-metil-piperidinil]-1-ciclopropil-1,4-dihidro-8-metoxi-4-oxo-3-quinolincarboxilico |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |